---
title: "SMMT: Ivonescimab achieved landmark Phase III survival results and FDA BLA acceptance, with strong cash reserves"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/293661481.md"
description: "Ivonescimab demonstrated significant overall survival benefits in multiple Phase III NSCLC trials, with consistent efficacy across regions and a strong safety profile. Financially, cash reserves remain robust at $690.7 million, and the FDA accepted the BLA for ivonescimab, with a decision expected in November 2026.Original document: Summit Therapeutics Inc. [SMMT] SEC 8-K Current Report — Jul. 23 2026DisclaimerThis is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source."
datetime: "2026-07-23T20:12:33.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/293661481.md)
  - [en](https://longbridge.com/en/news/293661481.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/293661481.md)
generator: "portal-rs"
---

# SMMT: Ivonescimab achieved landmark Phase III survival results and FDA BLA acceptance, with strong cash reserves

Ivonescimab demonstrated significant overall survival benefits in multiple Phase III NSCLC trials, with consistent efficacy across regions and a strong safety profile. Financially, cash reserves remain robust at $690.7 million, and the FDA accepted the BLA for ivonescimab, with a decision expected in November 2026.

Original document: Summit Therapeutics Inc. \[SMMT\] SEC 8-K Current Report — Jul. 23 2026

**Disclaimer**

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.

### Related Stocks

- [SMMT.US](https://longbridge.com/en/quote/SMMT.US.md)

## Related News & Research

- [Ivonescimab regimen shows OS superiority in Phase III HARMONi-GI1, Summit Therapeutics notes](https://longbridge.com/en/news/297053863.md)
- [Summit says FDA sets Nov. 14, 2026 action date for ivonescimab lung cancer filing](https://longbridge.com/en/news/296901535.md)
- [Taysha Gene Therapies highlights TSHA-102 Rett gene therapy path toward BLA submission in corporate presentation](https://longbridge.com/en/news/297550820.md)
- [uniQure Filed for Huntington's Approval. Acceptance Is the Catalyst, Analyst Says](https://longbridge.com/en/news/297819704.md)
- [BiomX set to execute 1-for-10 reverse stock split Sept. 9](https://longbridge.com/en/news/297659721.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**